Study on the Mass Balance of [14C]HRS-9190 for Injection in Healthy Participants

Inclusion criteria

• The participants have been fully informed of the nature, significance, potential benefits, possible inconveniences, and potential risks and discomforts of the trial prior to its commencement.
• Male participants aged between 18 and 45 years old (inclusive);
• ASA =I;
• Male participants with a body weight of ≥ 50 kg and a body mass index (BMI = weight (kg)/height² (m²)) ranging from 19 to 28 kg/m² (inclusive) during the screening period;
• Male participants must agree to use highly effective contraception and refrain from donating semen from the time of signing the informed consent form until 4 months after the last administration of the investigational product.

Exclusion criteria

• Participants with a history of or current acute or chronic clinical diseases
• Participants with a history of neuromuscular diseases;
• Participants with a history of anesthetic complications;
• Participants with a history of airway diseases;
• Participants who have undergone major surgery within 6 months prior to screening;
• During the screening or baseline period: participants with clinically significant abnormal physical examination findings as judged by the investigator;
• Participants who test positive for one or more of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), syphilis antibody, or human immunodeficiency virus antibody (anti-HIV);
• Participants with a known history of allergy to the study drug; a history of anaphylactic shock; or atopic diathesis;
• Participants with contraindications to anesthetic agents;
• Participants who use hepatic enzyme inhibitors/inducers (within 1 month prior to dosing), vaccines (within 1 month pre-screening or planned during trial), or any drugs/health products (within 7 half-lives or 14 days pre-dosing);
• Participants who have participated in other clinical trials and received investigational products within 3 months prior to screening, or plan to participate in other clinical trials during the trial period;
• Participants with history of significant blood loss/transfusion (≥400 mL within 3 months), active tobacco (>5 cigarettes/day), excessive alcohol/coffee consumption, use of interfering substances (e.g., grapefruit, caffeine) within 48h prior to dosing, or evidence of drug abuse;
• Participants with difficult venous access;
• Occupational radiation workers; individuals with ≥2 CTs or ≥3 X-rays in the past year; participants in radiolabeled trials (within 1 year);
• Participants who may be unable to complete the study for other reasons or are deemed unsuitable for enrollment by the investigator.